Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from William Blair

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga

SpaceX stock falls back to earth shortly after Wall Street analysts release florid targets: 'Paving the superhighway to the stars'

A wave of wildly bullish price targets from Wall Street's SpaceX underwriters arrived just before the stock fell—raising questions about how much analysts really know.

Fortune

Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference

Chime Financial (NASDAQ:CHYM) founder and CEO Chris Britt outlined the digital banking company’s growth strategy, product roadmap and margin targets during a presentation at the William Blair conference, emphasizing Chime’s focus on primary checking relationships and mainstream U.S. consumers. Brit

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

American Public Education Unveils 2029 Growth Plan Fueled by Military and Nursing Programs

American Public Education (NASDAQ:APEI) outlined a four-year growth plan at a William Blair conference, with Chief Executive Officer Angie Selden saying the company expects revenue and adjusted earnings growth to be driven by its military-focused education business and its nursing education platform

MarketBeat

Dear Oklo Stock Fans, Mark Your Calendars for July 4

Investors dumped OKLO after its quarterly report recently. But Wall Street knows July 4 could be the real fireworks show for this next-generation nuclear bet.

Barchart

Hubble revisits the Crab Nebula after 25 years | Space photo of the day for March 24, 2026

NASA has released new Hubble telescope images of the Crab Nebula taken 25 years after the iconic observatory first gazed at the colorful cosmic crustacean.

Space

Old tech can learn new tricks. Colorful comparison photos of Crab Nebula wouldn’t have been possible with newer telescopes, NASA says

Images of the same colorful nebulae 25 years apart are a key example of why the Hubble Space Telescope's longevity matters

Digital Camera World

Read news from The Economist, FT, and more,
with one subscription

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.

Benzinga

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).

Benzinga

Medtronic Scores FDA Win As Hugo Surgical Robot Enters 230,000 Urology Procedure Market

On Wednesday, the U.S. Food and Drug Administration (FDA) cleared Medtronic Plc’s (NYSE:MDT) Hugo robotic-assisted surgery (RAS) system for use in urologic surgical procedures.

Benzinga

Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound

Simulations Plus Inc. (NASDAQ:SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.

Benzinga

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ:JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Benzinga

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

On Wednesday, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

International Business Times UK

Fiserv Stock Crashes 44% With CEO Exit, $30 Billion Wiped Out

Fiserv's stock plunges 44%, erasing £24B in value as growth slows, legal troubles rise, and leadership changes unsettle investors.

Benzinga

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga

Intuitive Surgical Q3 Results Ease Bear Market Concerns, Analyst Views 'Headwinds As Largely Noise'

Intuitive Surgical (NASDAQ:ISRG) reported revenue of $2.51 billion for the third quarter, up 23% year-over-year, beating analyst estimates of $2.40 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Tesla Just Set a New Quarterly Delivery Record. Should You Buy TSLA Stock Here?

Tesla’s quarterly deliveries climb to a record 497,100 units in the third quarter. William Blair says it’s getting hard to stick with its neutral stance on TSLA stock.

Benzinga

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

Benzinga

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals

The U.S. Food and Drug Administration on Thursday introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.